Please login to the form below

Not currently logged in
Email:
Password:

Cardax adds big pharma experience to board

Brings in former Novartis, BMS and Boehringer executives

tamar howson cardaxHawaii-based anti-inflammatory specialist Cardax has added three new members to its board, each with experience at a major pharma company.

George Bickerstaff is a former chief financial officer of Novartis who is now managing director at investment bank MM Dillon. He was also chief financial officer at IMS Health.

Tamar Howson (pictured right) is a former senior business development executive at Bristol-Myers Squibb and SmithKline Beecham (now GSK) who now acts as an independent consultant to life sciences companies.

The final new addition is Terence Kelly who provides Cardax with scientific experience having served as VP, department of medicinal chemistry at Boehringer Ingelheim. He is currently president and CEO of CoMentis, a private biotech company focused on neurodegenerative diseases.

“The distinctive, yet complementary skills of our new board members provide a strong foundation as we develop and commercialise our nutraceutical and pharmaceutical programmes,” said David Watumull, president and CEO of Cardax.

These programmes are focused on developing products that are as effective as steroids and NSAIDS but have safer profiles.

19th June 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics